Trial watch: Naked and vectored DNA-based anticancer vaccines

References

• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, Palucka K. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. SnapShot: cancer vaccines. Cell 2014; 157:516-e1; PMID:24725415; http://dx.doi.org/10.1016/j.cell.2014.03.044
   PubMedGoogle Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
   PubMed Web of Science ®Google Scholar
• Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, et al. Trial watch: dendritic cell-based anticancer therapy. Oncoimmunology 2014; 3: e963424; http://dx.doi.org/10.4161/21624011.2014.963424
   Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/onci.23803
   PubMed Web of Science ®Google Scholar
• Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: A new target for cancer vaccines. Oncoimmunology 2013; 2:e23140; PMID:23802067; http://dx.doi.org/10.4161/onci.23140
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci 2013; 342:1432-3
   Google Scholar
• Pardoll D. Immunotherapy: it takes a village. Science 2014; 344:149; PMID:24723594; http://dx.doi.org/10.1126/science.344.6180.149-a
   PubMedGoogle Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi.org/10.1038/nri1592
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vergote I, Van Gool SW. Dendritic cell-based immunotherapy in ovarian cancer. Oncoimmunology 2013; 2:e27059; PMID:24501688; http://dx.doi.org/10.4161/onci.27059
   PubMedGoogle Scholar
• Aruga A. Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens. Oncoimmunology 2013; 2:e24882; PMID:24073370; http://dx.doi.org/10.4161/onci.24882
   PubMedGoogle Scholar
• Ricupito A, Grioni M, Calcinotto A, Bellone M. Boosting anticancer vaccines: too much of a good thing? Oncoimmunology 2013; 2:e25032; PMID:24073378; http://dx.doi.org/10.4161/onci.25032
   PubMedGoogle Scholar
• Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: the making and unmaking of a T-cell graveyard. Oncoimmunology 2013; 2:e24743; PMID:24073366; http://dx.doi.org/10.4161/onci.24743
   PubMed Web of Science ®Google Scholar
• Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007; 6:591-603; PMID:17669012; http://dx.doi.org/10.1586/14760584.6.4.591
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Oncoimmunology 2013; 2:e23403; PMID:23802081; http://dx.doi.org/10.4161/onci.23403
   PubMed Web of Science ®Google Scholar
• Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007; 104:8947-52; PMID:17517626; http://dx.doi.org/10.1073/pnas.0703395104
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; http://dx.doi.org/10.1038/nrc2326
   PubMed Web of Science ®Google Scholar
• Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; PMID:20368780; http://dx.doi.org/10.1155/2010/174378
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010; 22:264-70; PMID:20172703; http://dx.doi.org/10.1016/j.coi.2010.01.019
   PubMed Web of Science ®Google Scholar
• Teja Colluru V, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol 2013
   Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
   PubMed Web of Science ®Google Scholar
• Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216; PMID:17383089; http://dx.doi.org/10.1016/j.canlet.2007.02.002
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
   PubMed Web of Science ®Google Scholar
• Collet G, Grillon C, Nadim M, Kieda C. Trojan horse at cellular level for tumor gene therapies. Gene 2013; 525:208-16; PMID:23542073; http://dx.doi.org/10.1016/j.gene.2013.03.057
   PubMed Web of Science ®Google Scholar
• Khan AS, Broderick KE, Sardesai NY. Clinical development of intramuscular electroporation: providing a "boost" for DNA vaccines. Methods Mol Biol 2014; 1121:279-89; PMID:24510832; http://dx.doi.org/10.1007/978-1-4614-9632-8_25
   PubMedGoogle Scholar
• Mohler VL, Heithoff DM, Mahan MJ, Hornitzky MA, Thomson PC, House JK. Development of a novel in-water vaccination protocol for DNA adenine methylase deficient Salmonella enterica serovar Typhimurium vaccine in adult sheep. Vaccine 2012; 30:1481-91; PMID:22214887; http://dx.doi.org/10.1016/j.vaccine.2011.12.079
   PubMedGoogle Scholar
• Lewis GK. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev Vaccines 2007; 6:431-40; PMID:17542757; http://dx.doi.org/10.1586/14760584.6.3.431
   PubMed Web of Science ®Google Scholar
• Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014; 63:225-34; PMID:24327292; http://dx.doi.org/10.1007/s00262-013-1505-8
   PubMed Web of Science ®Google Scholar
• Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostbock S, Tucker JA, Jochems C, Schlom J, Gulley JL, et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 2008; 26:509-21; PMID:18155327; http://dx.doi.org/10.1016/j.vaccine.2007.11.033
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Muller M, Roohvand F, Motevalli F, Agi E, Shokri M, Rad MM, Hosseinzadeh S. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Hum Vaccin Immunother 2014; 10:3499-508; PMID:25668661; http://dx.doi.org/10.4161/21645515.2014.979606
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 17:359-71; PMID:21952287; http://dx.doi.org/10.1097/PPO.0b013e3182325e63
   PubMed Web of Science ®Google Scholar
• Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, Seymour LW. Recombinant viral vaccines for cancer. Trends Mol Med 2012; 18:564-74; PMID:22917663; http://dx.doi.org/10.1016/j.molmed.2012.07.007
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.1126/science.1088547
   PubMed Web of Science ®Google Scholar
• Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 2014; 25(4):301-17; PMID:24580050
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 2003; 21:401-18; PMID:12531639; http://dx.doi.org/10.1016/S0264-410X(02)00472-3
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012; 12:361; PMID:22906006; http://dx.doi.org/10.1186/1471-2407-12-361
   PubMed Web of Science ®Google Scholar
• Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 2002; 102:629-37; PMID:12448006; http://dx.doi.org/10.1002/ijc.10759
   PubMed Web of Science ®Google Scholar
• Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013; 4:1777-90; PMID:24125763
   PubMed Web of Science ®Google Scholar
• Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther 2011; 18:827-34; PMID:21390072; http://dx.doi.org/10.1038/gt.2011.28
   PubMed Web of Science ®Google Scholar
• Zhang T, Sun L, Xin Y, Ma L, Zhang Y, Wang X, Xu K, Ren C, Zhang C, Chen Z, et al. A vaccine grade of yeast Saccharomyces cerevisiae expressing mammalian myostatin. BMC Biotechnol 2012; 12:97; PMID:23253888; http://dx.doi.org/10.1186/1472-6750-12-97
   PubMed Web of Science ®Google Scholar
• Kugelberg E. Dendritic cells: TLR agonists trigger rapid metabolic changes. Nat Rev Immunol 2014; 14:209; PMID:24662378; http://dx.doi.org/10.1038/nri3652
   PubMedGoogle Scholar
• Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 2014; 9:e83884; PMID:24404140; http://dx.doi.org/10.1371/journal.pone.0083884
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
   PubMedGoogle Scholar
• Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23:5263-70; PMID:16081189; http://dx.doi.org/10.1016/j.vaccine.2005.06.024
   PubMed Web of Science ®Google Scholar
• Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27:5450-9; PMID:19622402; http://dx.doi.org/10.1016/j.vaccine.2009.07.005
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40:86-97; PMID:16997717; http://dx.doi.org/10.1016/j.ymeth.2006.05.022
   PubMed Web of Science ®Google Scholar
• Hallermalm K, Johansson S, Brave A, Ek M, Engstrom G, Boberg A, Gudmundsdotter L, Blomberg P, Mellstedt H, Stout R, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007; 66:43-51; PMID:17587345; http://dx.doi.org/10.1111/j.1365-3083.2007.01945.x
   PubMed Web of Science ®Google Scholar
• Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dorken B, Norley S, Lipp M, Walther W, Pezzutto A, et al. HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology 2012; 1:1537-45; PMID:23264900; http://dx.doi.org/10.4161/onci.22563
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J, Woerdeman LA, Hennink WE, Storm G, Schumacher TN, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20:181-9; PMID:19301471; http://dx.doi.org/10.1089/hum.2008.073
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, Bins AD. Intradermal vaccination by DNA tattooing. Methods Mol Biol 2014; 1143:131-40; PMID:24715286; http://dx.doi.org/10.1007/978-1-4939-0410-5_9
   PubMedGoogle Scholar
• Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 2011; 11:447-56; PMID:22023474; http://dx.doi.org/10.2174/156652311798192860
   PubMed Web of Science ®Google Scholar
• Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174:6292-8; PMID:15879128; http://dx.doi.org/10.4049/jimmunol.174.10.6292
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165:2850-8; PMID:10946318; http://dx.doi.org/10.4049/jimmunol.165.5.2850
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; PMID:24404424; http://dx.doi.org/10.4161/onci.26536
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi.org/10.1038/nrm3479
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428
   PubMed Web of Science ®Google Scholar
• Olson BM, McNeel DG. Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines 2012; 11:1315-7; PMID:23249231; http://dx.doi.org/10.1586/erv.12.107
   PubMed Web of Science ®Google Scholar
• Monjazeb AM, Zamora AE, Grossenbacher SK, Mirsoian A, Sckisel GD, Murphy WJ. Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol 2013; 3:197; PMID:23898464; http://dx.doi.org/10.3389/fonc.2013.00197
   PubMedGoogle Scholar
• Maletzki C, Stier S, Linnebacher M. Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who? Oncoimmunology 2013; 2:e25419; PMID:24167765; http://dx.doi.org/10.4161/onci.25419
   PubMedGoogle Scholar
• Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10:294-8; PMID:14981514; http://dx.doi.org/10.1038/nm999
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang J, Li Z, Yang S. Evolution of the strategies for screening and identifying human tumor antigens. Curr Protein Pept Sci 2014; 15:819-27; PMID:25345657; http://dx.doi.org/10.2174/1389203715666141027100331
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11:263-70; PMID:10514004; http://dx.doi.org/10.1016/S1074-7613(00)80101-6
   PubMed Web of Science ®Google Scholar
• Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7:297-303; PMID:11231627; http://dx.doi.org/10.1038/85438
   PubMed Web of Science ®Google Scholar
• Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother 2014; PMID:25164877
   PubMedGoogle Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23-34; PMID:21048000; http://dx.doi.org/10.1128/CVI.00286-10
   PubMed Web of Science ®Google Scholar
• Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile R. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 2012; 23:1054-64; PMID:22734672; http://dx.doi.org/10.1089/hum.2012.030
   PubMed Web of Science ®Google Scholar
• Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2:e27010; PMID:24498547; http://dx.doi.org/10.4161/onci.27010
   PubMed Web of Science ®Google Scholar
• Dao T, Liu C, Scheinberg DA. Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology 2013; 2:e24678; PMID:24073363; http://dx.doi.org/10.4161/onci.24678
   PubMedGoogle Scholar
• Scanlon CS, D'Silva NJ. Personalized medicine for cancer therapy: lessons learned from tumor-associated antigens. Oncoimmunology 2013; 2:e23433; PMID:23734304; http://dx.doi.org/10.4161/onci.23433
   PubMedGoogle Scholar
• Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30C:24-31; http://dx.doi.org/10.1016/j.coi.2014.05.009
   Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256-61; PMID:17875753; http://dx.doi.org/10.1158/1078-0432.CCR-07-0892
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206-12; PMID:14578884; http://dx.doi.org/10.1038/ni1003
   PubMed Web of Science ®Google Scholar
• Wang RF. Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 2006; 28:17-23; PMID:16838179; http://dx.doi.org/10.1007/s00281-006-0022-7
   PubMedGoogle Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Fioretti D, Iurescia S, Rinaldi M. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat Anticancer Drug Discov 2014; 9:66-82; PMID:23444943
   PubMedGoogle Scholar
• Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75:4040-7; PMID:11287553; http://dx.doi.org/10.1128/JVI.75.9.4040-4047.2001
   PubMed Web of Science ®Google Scholar
• Anderson ED, Mourich DV, Leong JA. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Mol Mar Biol Biotechnol 1996; 5:105-13; PMID:8680523
   PubMedGoogle Scholar
• Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol 1996; 5:114-22; PMID:8680524
   PubMedGoogle Scholar
• Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284-90; PMID:12684396
   PubMed Web of Science ®Google Scholar
• USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 2010; 236:495; PMID:20187810; http://dx.doi.org/10.2460/javma.236.5.488
   PubMed Web of Science ®Google Scholar
• Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, et al. Trial watch: padioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e28694. in press; PMID:25097804
   PubMedGoogle Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
   PubMed Web of Science ®Google Scholar
• Compte M, Alvarez-Cienfuegos A, Nunez-Prado N, Sainz-Pastor N, Blanco-Toribio A, Pescador N, Sanz L, Alvarez-Vallina L. Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology 2014; 3:e28810; PMID:25057445; http://dx.doi.org/10.4161/onci.28810
   PubMed Web of Science ®Google Scholar
• Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 2002; 62:5049-57; PMID:12208760
   PubMed Web of Science ®Google Scholar
• Wang D, Rayani S, Marshall JL. Carcinoembryonic antigen as a vaccine target. Expert Rev Vaccines 2008; 7:987-93; PMID:18767948; http://dx.doi.org/10.1586/14760584.7.7.987
   PubMed Web of Science ®Google Scholar
• Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2002; 2:709-35; PMID:12503217; http://dx.doi.org/10.1586/14737140.2.6.709
   PubMedGoogle Scholar
• Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S, Zhu JY. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004; 10:2034-8; PMID:15237429
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290-300; PMID:22374331; http://dx.doi.org/10.1158/1078-0432.CCR-11-2175
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101:524-32; PMID:16542289; http://dx.doi.org/10.1111/j.1572-0241.2006.00443.x
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med 2014; 12:86; PMID:24708667; http://dx.doi.org/10.1186/1479-5876-12-86
   PubMed Web of Science ®Google Scholar
• Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat 2013; 138:109-18; PMID:22678162; http://dx.doi.org/10.1007/s10549-012-2110-9
   PubMed Web of Science ®Google Scholar
• Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, Fleming TP. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59:3028-31; PMID:10397237
   PubMed Web of Science ®Google Scholar
• Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56:860-5; PMID:8631025
   PubMed Web of Science ®Google Scholar
• Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004; 37:249-57; PMID:15003725; http://dx.doi.org/10.1016/j.clinbiochem.2003.11.005
   PubMed Web of Science ®Google Scholar
• Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, MaC, Naughton M, Lockhart AC, Gao F, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 2014; 20:5964-75; PMID:25451106; http://dx.doi.org/10.1158/1078-0432.CCR-14-0059
   PubMed Web of Science ®Google Scholar
• Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236:229-38; PMID:16046056; http://dx.doi.org/10.1016/j.canlet.2005.05.021
   PubMed Web of Science ®Google Scholar
• Dale W. Prostate cancer: PSA testing in older men–are we following the guidelines? Nat Rev Urol 2012; 9:357-8; PMID:22641163; http://dx.doi.org/10.1038/nrurol.2012.115
   PubMedGoogle Scholar
• Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800-7; PMID:10582702
   PubMed Web of Science ®Google Scholar
• Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 2000; 92:1228-39; PMID:10922408; http://dx.doi.org/10.1093/jnci/92.15.1228
   PubMed Web of Science ®Google Scholar
• Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003; 63:7942-9; PMID:14633725
   PubMed Web of Science ®Google Scholar
• Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther 2012; 12:463-78; PMID:22413824; http://dx.doi.org/10.1517/14712598.2012.668516
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999; 39:291-7; PMID:10344219; http://dx.doi.org/10.1002/(SICI)1097-0045(19990601)39:4%3c291::AID-PROS10%3e3.0.CO;2-9
   PubMedGoogle Scholar
• Arellano M, Lonial S. Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2008; 2:13-27; PMID:19707424
   PubMedGoogle Scholar
• Thorne SH. The role of GM-CSF in enhancing immunotherapy of cancer. Immunotherapy 2013; 5:817-9; PMID:23902549; http://dx.doi.org/10.2217/imt.13.65
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, et al. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 2014; pii: S0302-2838(14):01265-2; PMID:25533418
   PubMedGoogle Scholar
• Madan RA, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. Oncoimmunology 2014; 3:e28611; PMID:25097802; http://dx.doi.org/10.4161/onci.28611
   PubMedGoogle Scholar
• DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4:1; PMID:16390546; http://dx.doi.org/10.1186/1479-5876-4-1
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597
   PubMed Web of Science ®Google Scholar
• May KF, Jr., Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res 2011; 17:5233-8; PMID:21700764; http://dx.doi.org/10.1158/1078-0432.CCR-10-3402
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014; 33(2-3):641-55; PMID:24477411
   PubMedGoogle Scholar
• De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res 2014; 16:R10; PMID:24451168; http://dx.doi.org/10.1186/bcr3602
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84; PMID:16236738; http://dx.doi.org/10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• Spicer J, Harries M, Ellis P. Adjuvant trastuzumab for HER2-positive breast cancer. Lancet 2005; 366:634; PMID:16112298; http://dx.doi.org/10.1016/S0140-6736(05)67134-6
   PubMedGoogle Scholar
• Disis ML, Coveler AL, Higgins D, Fintak P, Waisman JR, Reichow J, Slota M, Childs J, Dang Y, Salazar LG. A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. ASCO Meeting Abstracts 2014; 32:616
   Google Scholar
• Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465-72; PMID:23455713; http://dx.doi.org/10.1038/nm.3105
   PubMed Web of Science ®Google Scholar
• Patel PM, Durrant LG, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Cunnell M, Metheringham R, Brentville V, Machado L, et al. Phase I trial of ImmunoBody in melanoma patients. ASCO Meeting Abstracts 2014; 32:3061
   Google Scholar
• Durrant LG, Pudney VA, Spendlove I. Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines 2011; 10:1093-106; PMID:21806402; http://dx.doi.org/10.1586/erv.11.33
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab Z, DeMatos P, Hester D, Dong XD, Seigler HF. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Cell Immunol 1998; 186:63-74; PMID:9637766; http://dx.doi.org/10.1006/cimm.1998.1298
   PubMedGoogle Scholar
• Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188:277-86; PMID:9670040; http://dx.doi.org/10.1084/jem.188.2.277
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66:4943-51; PMID:16651452; http://dx.doi.org/10.1158/0008-5472.CAN-05-3396
   PubMed Web of Science ®Google Scholar
• Tuting T, Steitz J, Bruck J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400-6; PMID:10753065; http://dx.doi.org/10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.0.CO;2-D
   PubMedGoogle Scholar
• Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005; 65:7007-12; PMID:16061687; http://dx.doi.org/10.1158/0008-5472.CAN-05-0938
   PubMed Web of Science ®Google Scholar
• Singh H, Heery CR, Marte JL, Farsaci B, Madan RA, O'Sullivan Coyne GH, Palena C, Rodell TC, Schlom J, Gulley JL. A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. ASCO Meeting Abstracts 2014; 32:e14026
   Google Scholar
• Sarkar D, Shields B, Davies ML, Muller J, Wakeman JA. Brachyury confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer 2012; 130:328-37; PMID:21365650; http://dx.doi.org/10.1002/ijc.26029
   PubMedGoogle Scholar
• Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007; 13:2471-8; PMID:17438107; http://dx.doi.org/10.1158/1078-0432.CCR-06-2353
   PubMed Web of Science ®Google Scholar
• Pires MM, Aaronson SA. Brachyury: a new player in promoting breast cancer aggressiveness. J Natl Cancer Inst 2014; 106:pii: dju094; PMID:24815862; http://dx.doi.org/10.1093/jnci/dju094
   PubMedGoogle Scholar
• Thoma C. Prostate cancer: Brachyury–a biomarker for progression and prognosis? Nat Rev Urol 2014; 11:485; PMID:25069730; http://dx.doi.org/10.1038/nrurol.2014.184
   PubMedGoogle Scholar
• Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother 2014; 63:1307-17; PMID:25186612; http://dx.doi.org/10.1007/s00262-014-1603-2
   PubMedGoogle Scholar
• Almajhdi FN, Senger T, Amer HM, Gissmann L, Ohlschlager P. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). PLoS One 2014; 9:e113461; PMID:25422946; http://dx.doi.org/10.1371/journal.pone.0113461
   PubMed Web of Science ®Google Scholar
• Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, DisisML. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 2014; 74:2710-8; PMID:24778415; http://dx.doi.org/10.1158/0008-5472.CAN-13-3286
   PubMedGoogle Scholar
• Gan L, Jia R, Zhou L, Guo J, Fan M. Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One 2014; 9:e108892; PMID:25265018; http://dx.doi.org/10.1371/journal.pone.0108892
   PubMedGoogle Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Xiao Y, Wang Y, Dong J, Gao K, Gao Y, Wang X, Zhang W, Xu Y, et al. Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus. PLoS One 2014; 9:e90551; PMID:24608380; http://dx.doi.org/10.1371/journal.pone.0090551
   PubMedGoogle Scholar
• Bertino P, Urschitz J, Hoffmann FW, You BR, Rose AH, Park WH, Moisyadi S, Hoffmann PR. Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responses. Vaccine 2014; 32:1670-7; PMID:24513010; http://dx.doi.org/10.1016/j.vaccine.2014.01.063
   PubMed Web of Science ®Google Scholar
• Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, Chen Y, Sun B. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol 2014; 11:184-96; PMID:24488178; http://dx.doi.org/10.1038/cmi.2013.64
   PubMed Web of Science ®Google Scholar
• Rangel-Colmenero BR, Gomez-Gutierrez JG, Villatoro-Hernandez J, Zavala-Flores LM, Quistian-Martinez D, Rojas-Martinez A, Arce-Mendoza AY, Guzmán-López S, Montes-de-Oca-Luna R, Saucedo-Cárdenas O. Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. Viral Immunol 2014; 27:463-7; PMID:25216057; http://dx.doi.org/10.1089/vim.2014.0055
   PubMed Web of Science ®Google Scholar
• Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F, Kelishadi M. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci 2014; 21:69; PMID:25077570; http://dx.doi.org/10.1186/s12929-014-0069-z
   PubMedGoogle Scholar
• Toke ER, Lorincz O, Csiszovszki Z, Somogyi E, Felfoldi G, Molnar L, Szipőcs R, Kolonics A, Malissen B, Lori F, et al. Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes. Gene Ther 2014; 21:566-74; PMID:24694539; http://dx.doi.org/10.1038/gt.2014.29
   PubMed Web of Science ®Google Scholar
• Li J, Valentin A, Ng S, Beach RK, Alicea C, Bergamaschi C, Felber BK, Pavlakis GN. Differential effects of IL-15 on the generation, maintenance and cytotoxic potential of adaptive cellular responses induced by DNA vaccination. Vaccine 2015; 33:1188-96; PMID:25559187; http://dx.doi.org/10.1016/j.vaccine.2014.12.046
   PubMed Web of Science ®Google Scholar
• Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583-94; PMID:23567086; http://dx.doi.org/10.1016/j.jhep.2013.03.033
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Wei F, Yang D, Tewary P, Li Y, Li S, Chen X, Howard OM, Bustin M, Oppenheim JJ. The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant. Cancer Res 2014; 74:5989-98; PMID:25205103; http://dx.doi.org/10.1158/0008-5472.CAN-13-2042
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74:1789-800; PMID:24448242; http://dx.doi.org/10.1158/0008-5472.CAN-13-2729
   PubMed Web of Science ®Google Scholar
• Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One 2014; 9:e93162; PMID:24664420; http://dx.doi.org/10.1371/journal.pone.0093162
   PubMedGoogle Scholar
• Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res 2014; 20:5456-67; PMID:24893628; http://dx.doi.org/10.1158/1078-0432.CCR-14-0344
   PubMed Web of Science ®Google Scholar
• Semeraro M, Galluzzi L. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; http://dx.doi.org/10.4161/onci.28386
   PubMed Web of Science ®Google Scholar
• Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/onci.26494
   PubMed Web of Science ®Google Scholar
• Sakamaki I, Kwak LW, Cha SC, Yi Q, Lerman B, Chen J, Surapaneni S, Bateman S, Qin H. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 2014; 28:329-37; PMID:23765229; http://dx.doi.org/10.1038/leu.2013.177
   PubMed Web of Science ®Google Scholar
• Li SQ, Lin J, Qi CY, Fu SJ, Xiao WK, Peng BG, Liang LJ. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. Hepatogastroenterology 2014; 61:278-84; PMID:24901124
   PubMedGoogle Scholar
• Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther 2014; 21:507-17; PMID:25394503; http://dx.doi.org/10.1038/cgt.2014.56
   PubMed Web of Science ®Google Scholar
• Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A, et al. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 2014; 5:12803-10; PMID:25296974
   PubMedGoogle Scholar
• Polakova I, Duskova M, Smahel M. Antitumor DNA vaccination against the Sox2 transcription factor. Int J Oncol 2014; 45:139-46; PMID:24789529
   PubMedGoogle Scholar
• Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, et al. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 2014; 124:1497-511; PMID:24642465; http://dx.doi.org/10.1172/JCI67382
   PubMed Web of Science ®Google Scholar
• Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L, et al. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Res 2014; 74:6010-21; PMID:25125656; http://dx.doi.org/10.1158/0008-5472.CAN-14-0473
   PubMed Web of Science ®Google Scholar
• Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries–key challenges and issues. N Engl J Med 2007; 356:1908-10; PMID:17494923; http://dx.doi.org/10.1056/NEJMp078053
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther 2011; 19:1793-801; PMID:21505426; http://dx.doi.org/10.1038/mt.2011.77
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, Darasse-Jèze G, Telerman SB, Breton G, Schreiber HA, et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19:730-8; PMID:23685841; http://dx.doi.org/10.1038/nm.3197
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114:1241-4; PMID:15520855; http://dx.doi.org/10.1172/JCI23467
   PubMed Web of Science ®Google Scholar
• Michaud DS, Langevin SM, Eliot M, Nelson HH, Pawlita M, McClean MD, Kelsey KT. High-risk HPV types and head and neck cancer. Int J Cancer 2014; 135:1653-61; PMID:24615247; http://dx.doi.org/10.1002/ijc.28811
   PubMed Web of Science ®Google Scholar
• Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010; 21 Suppl 7:vii243-5; PMID:20943622
   PubMedGoogle Scholar
• Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Halon A, Lage H, Surowiak P. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res 2012; 32:3177-84; PMID:22843890
   PubMed Web of Science ®Google Scholar
• Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, Tan PH, Hains P, Valova VA, Huschtscha L, et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One 2011; 6:e20603; PMID:21695211; http://dx.doi.org/10.1371/journal.pone.0020603
   PubMedGoogle Scholar
• Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2013; 2:e25205; PMID:24073380; http://dx.doi.org/10.4161/onci.25205
   PubMedGoogle Scholar
• Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31:1354-65; PMID:21822303; http://dx.doi.org/10.1038/onc.2011.338
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: e955691; http://dx.doi.org/10.4161/21624011.2014.955691
   Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
   PubMed Web of Science ®Google Scholar
• Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 2013; 20:521-30; PMID:23928731; http://dx.doi.org/10.1038/cgt.2013.49
   PubMed Web of Science ®Google Scholar
• Eriksson F, Totterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine 2013; 31:3843-8; PMID:23831327; http://dx.doi.org/10.1016/j.vaccine.2013.06.063
   PubMed Web of Science ®Google Scholar
• Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-47; PMID:20551832; http://dx.doi.org/10.1097/CJI.0b013e3181dda23e
   PubMed Web of Science ®Google Scholar
• Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 2006; 24:434-41; PMID:16962496; http://dx.doi.org/10.1016/j.urolonc.2005.08.010
   PubMedGoogle Scholar
• Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. Anticancer Agents Med Chem 2013; 13:872-86; PMID:23272970; http://dx.doi.org/10.2174/18715206113139990077
   PubMedGoogle Scholar
• Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology 2013; 2:e26084; http://dx.doi.org/10.4161/onci.26084
   PubMed Web of Science ®Google Scholar
• Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 2012; 11:857-68; PMID:22913261; http://dx.doi.org/10.1586/erv.12.54
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3:e967147; http://dx.doi.org/10.4161/21624011.2014.967147
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014; 3: e957994; http://dx.doi.org/10.4161/21624011.2014.957994
   Google Scholar
• Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; PMID:23894726; http://dx.doi.org/10.4161/onci.25396
   PubMed Web of Science ®Google Scholar
• Riedmann EM. News studies: combining PROSTVAC with conventional cancer therapy. Hum Vaccin Immunother 2012; 8:848-9; http://dx.doi.org/10.4161/hv.22583
   Web of Science ®Google Scholar